
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is facing a downgrade to Hold due to concerns about future growth and a lack of near-term catalysts. This is largely due to the unexpected underperformance of Baqsimi in 1Q26, with a significant decrease in sales and expected price erosion. While the company is taking actions to address these issues, a return to prior levels of sales growth for Baqsimi is unlikely, leading to a flat-to-low single digit growth estimate for 2026.
Bears say
Amphastar Pharma is facing challenges in launching new products, with lower than expected revenue and earnings in the first quarter of 2026 due to pricing pressure and competition in the generics business. The company also has a number of complex generic and brand products in its pipeline, but the timeline for when these products may contribute to revenue is uncertain. As a result, there is a lack of visibility into the company's growth potential, leading to a negative outlook on the stock. Additionally, Amphastar's dependence on pipeline development for future success poses a high degree of risk.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares